Seres Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Seres Therapeutics (MCRB).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

2Buy

1Hold

2Sell

Consensus RatingBuy# Analysts5Avg. Consensus PT$14Upside to Avg. PT+587.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jun 23, 2026	HC Wainwright & Co.	Matthew Keller	Initiate	Buy	$12
Mar 13, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$22
Sep 24, 2025	Canaccord Genuity	John Newman	PT Raise	Buy	$14→$22
May 8, 2025	Chardan Capital	Keay Nakae	Downgrade	Buy→Neutral	$1→$6
Mar 20, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$25
Mar 14, 2025	Goldman Sachs	Chris Shibutani	PT Cut	Sell	$20→$15
Nov 14, 2024	Canaccord Genuity	John Newman	Maintained	Buy	$200
Nov 13, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$25
Oct 24, 2024	JP Morgan	Tessa Romero	Downgrade	Neutral→Underweight	—
Sep 13, 2024	Canaccord Genuity	John Newman	Maintained	Buy	$200
Aug 14, 2024	Canaccord Genuity	John Newman	Maintained	Buy	$200
Aug 14, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$25
Jun 7, 2024	Oppenheimer	Jeff Jones	Downgrade	Outperform→Perform	—
Jun 7, 2024	Canaccord Genuity	John Newman	PT Cut	Buy	$300→$200
May 9, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$100→$80
May 8, 2024	Chardan Capital	Keay Nakae	PT Cut	Buy	$160→$120
Mar 6, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$180→$100
Mar 6, 2024	Chardan Capital	Keay Nakae	PT Cut	Buy	$200→$160
Jan 16, 2024	Oppenheimer	Jeff Jones	PT Cut	Outperform	$200→$180
Nov 3, 2023	Goldman Sachs	Chris Shibutani	PT Cut	Sell	$80→$25

Analyst Ratings News

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Wall Street analysts changed outlook on top names, including MCRB, SAFX. See analyst ratings page for full coverage.

Avi Kapoor

PRO
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

HC Wainwright & Co. analyst Matthew Keller initiates coverage on Seres Therapeutics (NASDAQ:MCRB) with a Buy rating and announces Price Target of $12.

Benzinga Newsdesk

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Avi Kapoor

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

Avi Kapoor

PRO
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

Chardan Capital analyst Keay Nakae downgrades Seres Therapeutics (NASDAQ:MCRB) from Buy to Neutral and raises the price target from $1.25 to $6.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

Chardan Capital analyst Keay Nakae maintains Seres Therapeutics (NASDAQ:MCRB) with a Buy and maintains $1.25 price target.

Benzinga Newsdesk

Seres Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Seres Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PRO
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

PRO
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

PRO
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

People Also Watch

People Also Watch

Seres Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Seres Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

PROHC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday

PROChardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

PROChardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Initiates Coverage On Seres Therapeutics with Buy Rating, Announces Price Target of $12

PRO
Chardan Capital Downgrades Seres Therapeutics to Neutral, Raises Price Target to $6

PRO
Chardan Capital Maintains Buy on Seres Therapeutics, Maintains $1.25 Price Target